ICIs, especially the combination of anti-PD-L1 and anti-VEGF agents (e.g., atezolizumab and bevacizumab) or anti-PD-L1 and anti-CTLA-4 (e.g., durvalumab and tremelimumab), have demonstrated superior efficacy compared to sorafenib in first-line treatment of unresectable HCC, as evidenced by the IMbrave150 [3] and HIMALAYA trial [4]. This evidence concerns the gene CD274 and hepatocellular carcinoma.